2023 Targeted Therapies of Lung Cancer Meeting (Poster)-P1.16. Targetable Molecular Algorithm and Training Pathways Development for Treatment of the Non-Small Cell Lung Cancer

Pdf Summary

This research poster presentation discusses the use of tissue and/or blood biomarkers to guide treatment decisions for patients with advanced non-small cell lung cancer (NSCLC). The authors highlight the importance of obtaining tumor signature information quickly and accurately. They also address the challenges in implementing molecular diagnostics, particularly in community oncology settings. The authors mention a reduction in NSCLC mortality in the United States, which may be attributed to advancements in treatment, such as targeted therapies. However, they note that there is still a lack of knowledge regarding the appropriate testing and ordering of these therapies.<br /><br />The authors describe a project aimed at increasing the understanding and use of Next-Generation Sequencing (NGS) in NSCLC by developing a clinical pathway system called the Targetable Molecular Algorithm (TMA). The TMA includes pathways for seven major targetable mutations in NSCLC and helps guide clinicians in selecting the appropriate test and managing patients with specific mutations. The TMA is hosted on an online platform and includes references to clinical trials and drug information.<br /><br />To assess the impact of the TMA platform, the authors conducted surveys before and after its use. The surveys showed an increase in knowledge of NGS and targetable mutations among participants. The authors also reported a high level of satisfaction with the platform and a willingness to recommend it to others.<br /><br />The authors acknowledge the need for further research to evaluate the impact of the TMA platform on the utilization of NGS testing. They also highlight the importance of clinical pathways in guiding evidence-based practice and suggest that the TMA platform can help educate and inform providers about biomarker testing and its clinical consequences.<br /><br />Overall, this research highlights the importance of biomarker testing and the potential benefits of using a clinical pathway system like the TMA to improve the understanding and utilization of NGS in NSCLC treatment.

Asset Subtitle

Ayesha Munir, Medstar Georgetown Cancer Institute, United States

Meta Tag

Speaker Ayesha Munir, Medstar Georgetown Cancer Institute, United States

Topic Poster Listing

Keywords

tissue biomarkers

blood biomarkers

treatment decisions

NSCLC

molecular diagnostics

targeted therapies

Next-Generation Sequencing

TMA

clinical trials

biomarker testing